Qsam doses first patient in Cyclosam clinical trial

2020 11 19 22 35 3546 Femur Bone And Pelvis 400

Qsam Biosciences said the first patient has begun treatment in the company's clinical trial evaluating samarium-153-DOTMP (CycloSam) for the treatment of bone cancer and related diseases.

The study is a phase I open-label, dose-escalation trial to assess the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam. Patients with cancer that originated in the bone including osteosarcoma and Ewing's sarcoma are also eligible to participate.

Page 1 of 435
Next Page